Efforts have been undertaken recently to assess the fetal genome through analysis of circulating cell-free (ccf) fetal DNA obtained from maternal plasma. Sequencing analysis of such ccf DNA has been shown to enable accurate prenatal detection of fetal aneuploidies, including trisomies of chromosomes 21, 18, and 13. We sought to extend these analyses to examine subchromosomal copy number variants through the sequencing of ccf DNA. We examined a clinically relevant genomic region, chromosome 22q11.2, the location of a series of well-characterized deletion anomalies that cause 22q11.2 deletion syndrome.
RESULTS:
The median fetal DNA contribution for all samples was 18%, with the affected samples containing 17%-18% fetal DNA. Using a technique similar to that used for sequencing-based fetal aneuploidy detection from maternal plasma, we detected a statistically significant loss of representation of a portion of chromosome 22q11.2 in both of the affected fetal samples. No such loss was detected in any of the control samples.
CONCLUSIONS:
Noninvasive prenatal diagnosis of subchromosomal fetal genomic anomalies is feasible with next-generation sequencing.
The field of prenatal diagnostics has advanced with the implementation of techniques that enable the characterization of circulating cell-free (ccf) 3 fetal DNA isolated from maternal plasma. Using next-generation sequencing, multiple groups have shown that chromosomal aberrations can be detected reliably (1) (2) (3) (4) (5) (6) . Although the detection of trisomy 21 has been the most thoroughly validated to date-both analytically and in large-scale clinical studies-trisomies 13 and 18, sex aneuploidies, and other genetic aberrations will likely be similarly validated in the near future. One facet of genetic anomalies detected in other types of samples that has not yet been thoroughly addressed with ccf fetal DNA is subchromosomal copy number variation (CNV) (7 ) . Previous reports have shown that approximately 12% of individuals with unexplained developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies are diagnosed with clinically relevant CNV (7, 8 ) .
One example of such a genetic condition is 22q11.2 deletion syndrome, a disorder responsible for multiple conditions, including DiGeorge syndrome, velocardiofacial syndrome, and conotruncal anomalyface syndrome. These syndromes are linked to a heterozygous deletion of approximately 3 ϫ 10 6 bp on chromosome 22. Chromosome 22q11.2 deletion syndrome affects approximately 1 in 4000 live births and is characterized by frequent heart defects, cleft palate, developmental delays, and learning disabilities (9, 10 ) .
We designed this study to determine the technical feasibility of detecting subchromosomal CNV by sequencing ccf DNA obtained from maternal plasma. We examined maternal plasma samples from 2 women, each carrying a fetus confirmed by karyotype analysis to be affected by 22q11.2 deletion syndrome; as controls, we analyzed samples from 14 women at low risk for fetal aneuploidies. The ccf DNA from each sample was sequenced for a genomic coverage of approximately 4-fold. We were able to detect a statistically significant decrease in the representation of a region of 3 ϫ 10 6 bp on chromosome 22 that corresponds to the area known to be affected in the 2 verified cases.
Samples were collected under 2 separate investigational review board-approved clinical protocols (Western Institutional Review Board ID 20091396 and Compass Institutional Review Board 00462). The 2 blood samples from the affected patients were collected before an invasive procedure. The presence of a 22q11.2 microdeletion in these samples was confirmed by karyotype analysis of material obtained by nontransplacental amniocentesis. The 14 control samples were collected without a subsequent invasive proce-dure, and thus no karyotype information was available for these samples. All participants provided written informed consent before blood collection. Whole blood was collected and processed as previously described (3, 6 ) .
We extracted ccf DNA from maternal plasma with the QIAamp Circulating Nucleic Acid Kit (Qiagen), as previously described (3, 6 ) . The quantity of ccf DNA was assessed for each sample with the fetal quantifier assay, as previously described (3, 6, 11 ) .
Libraries were created with a modified version of the Illumina protocol for TruSeq library preparation. Extracted ccf DNA (40 L) was used for library preparation. All libraries were created via a semiautomated process that used liquid-handler instrumentation (Caliper Zephyr; Caliper Life Sciences) with a magnetic bead-based (Beckman Coulter) cleanup step after the end-repair, ligation, and PCR biochemical processes. Because ccf DNA has been repeatedly demonstrated to exist in maternal plasma within a small range of fragment sizes, we performed no size-selection procedures with either the extracted ccf DNA or the prepared libraries (12 ) . We performed size-distribution, quantification, and sequencing analyses of each sample as previously described (6 ) .
We analyzed the sequencing data as described previously (1, 6, 7, 13 ) . Counts of repeat-masked, GCnormalized, and unique aligned reads (1 mismatch allowed) for each 50-kb bin were used to calculate statistical significance and coverage. Statistical significance was determined by calculating a z score for the fraction of autosomal reads mapping to the region of interest relative to the total number of autosomal reads. z Scores were calculated via a previously described robust method: z Sample ϭ (Fraction Sample Ϫ Median Fraction Population )/Median Absolute Deviation Population (13 ) . Coverage was calculated with the formula: Coverage ϭ L ϫ N/G, where L is read length (36 bp), N is the number of repeat-masked, GC-normalized reads, and G is the size of the repeat-masked haploid genome.
Next-generation sequencing of ccf DNA isolated from plasma samples of the 16 pregnant women, 2 of whom were confirmed by karyotype analysis after amniocentesis to be carrying a fetus affected by chromosome 22q11.2 deletion syndrome. Plasma samples were collected from the 2 affected women at gestational ages (19 and 20 weeks) similar to those of the control samples (median, 20 weeks) (see Table 1 in the Data Supplement that accompanies the online version of this Brief Communication at http://www.clinchem.org/ content/vol58/issue7). All samples contained Ͼ10% fetal DNA (median contribution, 18%); the 2 samples carrying the fetal microdeletion contained 17% and 18% fetal DNA (see Table 1 in the online Data Supplement).
We sequenced each sample with 2 lanes of an Illumina HiSeq2000 flow cell, for a genomic coverage of 3.1-fold to 4.4-fold (see Table 1 in the online Data Supplement). Reads were binned at a bin size of 50 kb, and bins were visualized across chromosome 22 for the affected samples to confirm the location of the microdeletion. Both samples that carried the 22q11.2 microdeletion exhibited decreased representation in this genomic area (see Fig. 1 in the online Data Supplement). For statistical testing, we used a consensus region of 3 ϫ 10 6 bp located between Chr22:19000000 and Chr22:22000000 (see Fig. 1 and Table 1 in the online Data Supplement). We calculated the fraction and the z score for all autosomal reads that mapped to the target region. The control samples contained 0.075% of the reads mapping to 22q11, whereas the affected samples showed only 0.073% of reads in this region. Both affected samples had z scores lower than Ϫ3 (Ϫ5.4 and Ϫ7.1), whereas all samples from the lowrisk control individuals had z scores greater than Ϫ3 (Fig. 1) . Only one of the low-risk samples had a z score higher than ϩ3. Analogous to methods used for aneuploidy detection, in which z scores less than Ϫ3 are not evaluated, the clinical relevance of this finding is unclear. Repeated analysis of the 2 affected samples at increased sequencing depth (15.87-fold to 16.77-fold) For the region affected on chromosome 22, z scores were calculated for each sample relative to the median of all samples. Dashed line at Ϫ3 represents a z score that is 3 median absolute deviations lower than the median representation for this region across all analyzed samples and is the classification cutoff traditionally used in fetal aneuploidy detection.
confirmed the results (see Fig. 2 in the online Data Supplement).
Recent advances in the field of noninvasive prenatal diagnostics have facilitated the detection of fetal aneuploidies by sequencing of ccf DNA present in maternal plasma. Using a similar approach, the present study has demonstrated the feasibility of detecting subchromosome-level CNV in a developing fetus noninvasively via sequencing of the corresponding ccf DNA in maternal plasma. Albeit the number of cases is small, our data show that regions smaller than a single chromosome, in this case a deletion of 22q11.2, can be detected reliably in maternal plasma. The inclusion of additional affected and control samples would be beneficial for increasing the power of future studies. A recently published similar proof-of-concept study detected a 4.2-Mb deletion on chromosome 12 (14 ) . This study evaluated a single case of a fetal microdeletion and detected it in a sample containing 5.7% fetal DNA obtained at a late gestational age (35 weeks). The investigators compared the results with those obtained for 7 samples known to be diploid for chromosomes 12 and 14. In contrast, the present study examined affected samples obtained at an earlier gestational age (19 and 20 weeks), used twice the number of affected and unaffected samples, and detected a microdeletion 28% smaller (3 Mb) than that of the previous study, although in a sample with a higher fetal DNA contribution (17%-18%). To detect this 3-Mb fetal deletion in our study, we used a genomic coverage of 4-fold-an increase in coverage of approximately 20-fold over that of current standard aneuploidy detection. Smaller deletions (potentially down to 0.5 Mb) or samples containing less fetal ccf DNA will require even higher coverage (15 ) . Consequently, massively parallel shotgun sequencing will have to provide substantially higher throughput, or sequencing will have to be performed with a cost-effective targeted sequencing methodology before this method can be considered for routine clinical use.
When specific genetic aberrations are suspected, invasive procedures such as amniocentesis and chorionic villus sampling are used to provide genetic material for targeted cytogenetic analysis by well-established techniques, including G-banding, fluorescence in situ hybridization, quantitative fluorescence PCR, and microarrays (8, 16 ) . The transition from these methodologies to nontargeted, genome-wide analysis via massively parallel shotgun sequencing will first face several technical challenges, including the need for increased data-processing capacity and sufficient genome-wide sequencing coverage. Once these challenges are overcome, the medical community will be relied on to determine the most appropriate strategies for handling the increased information provided by these genomewide analyses, including CNVs of unknown significance. Although analyses will be performed and results will be obtained for the entire genome, these analyses should be indicated only in circumstances of a suspected fetal genetic anomaly, similar to the protocol currently used with invasive procedures. In contrast to methodologies that analyze fetal genetic material exclusively, ccf DNA analysis surely will also uncover CNVs present in the maternal genome. Before the implementation of such technology in the clinic, the medical community will need to evaluate the proper procedure for conveying such information. Despite the associated technical, medical, and ethical challenges, this novel extension of noninvasive prenatal aneuploidy detection has the potential to further advance recent progress in fetal-maternal medicine. 
